Immune Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IMUN research report →
Price Chart
About the company
Immune Therapeutics, Inc. currently conducts no significant business operations. Formerly known as TNI BioTech, Inc.
- CEO
- Noreen M. Griffin
- IPO
- 2010
- HQ
- Winter Park, FL, US
Get TickerSpark's AI analysis on IMUN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $7.78M
- P/E
- -0.01
- PEG
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -0.52
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 67.11%
- ROIC
- 43.69%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-1,163,000
- Net Income
- $-5,788,000-261.4%
- EPS
- $-0.16-102.2%
- OCF Growth
- -151.1%
- FCF Growth
- -366.9%
- 52W High
- $1.30
- 52W Low
- $0.07
- 50D MA
- $0.20
- 200D MA
- $0.48
- Beta
- 0.26
- RSI (14)
- 39
- Avg Volume
- 13.34K
No earnings-call transcripts are available for IMUN yet.
- Free Float
- 42.9%
- Shares Outstanding
- 83.62M
- Float Shares
- 35.87M
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 10, 23 | Farmer Glen A | buy | 409,000 |
| Jul 25, 22 | H. Louis Salomonsky Jr. Revocable Trust | other | 0 |
| Jul 25, 22 | Salomonsky Henry Louis | other | 0 |
| Jul 25, 22 | Salomonsky Henry Louis | other | 0 |
| Aug 2, 22 | Farmer Glen A | other | 0 |
| Aug 2, 22 | Farmer Glen A | other | 0 |
| Jun 30, 17 | Wilson Kelly O'Brien | other | 500 |
| Jul 25, 22 | Wilson Kelly O'Brien | other | 0 |
| Jul 25, 22 | Wilson Kelly O'Brien | other | 0 |
| Jul 25, 22 | Wilson Kelly O'Brien | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our IMUN coverage
Recent articles, reports, and earnings notes.
No research on IMUN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IMUN report →Critical Analysis: Immune Therapeutics (OTCMKTS:IMUN) & MBX Biosciences (NASDAQ:MBX)
defenseworld.net · Apr 4
32 Biosciences to Launch $40 Million Series A at J.P. Morgan to Advance First-in-Class GI Mucosal-Immune Therapeutics
businesswire.com · Jan 8
Biostax Corp Announces the Passing of Esteemed Director, H. Louis Salomonsky
globenewswire.com · Sep 14
Biostax Corp. Signs Collaboration Agreement with Immgenuity, Inc. to Pursue Remission in HIV
globenewswire.com · Aug 29
Biostax Corp Announces the FDAs Acceptance of Three Investigational New Drug Applications (IND) Transfers for JKB-122 for the Treatment of NASH, NAFLD and AIH
globenewswire.com · Aug 15
The 10 Most Shorted Stocks Right Now for Friday, Dec. 17
investorplace.com · Dec 17
Immune Therapeutics Announces Restructuring Plan
globenewswire.com · Jun 4
Immune Therapeutics FINRA Approval for 1:1000 Reverse Stock Split
globenewswire.com · May 11
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.